Inovio Pharmaceuticals Inc (INO)

[surf1944]

3:46AM Inovio Biomed achieves unprecedented T-Cell immune responses in human trial of DNA Vaccine for Cervical Dysplasia and Cancer caused by HPV (INO) 1.11 : Co announces preliminary data from Phase 1 dose escalation study of its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by HPV types 16 and 18. All dose groups developed significant antibody and T-cell immune responses; however, more notably, in the third and final dose group, five of six (83%) patients developed unprecedented T-cell responses not achieved by any other non-replicating vaccine platform in humans. Inovio is planning to start a Phase II clinical study in the 1Q11.